Leuprorelin Drugs Market Report 2026

Leuprorelin Drugs Market Overview

• Leuprorelin Drugs market size has reached to $2.88 billion in 2025 • Expected to grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Increasing Prevalence Of Prostate Cancer Fueling The Growth Of The Market Due To Rising Cases Among Aging Population • Market Trend: Ready-To-Use Injections Simplify Hormone Therapy Administration • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leuprorelin Drugs Market?

Leuprorelin drugs are synthetic gonadotropin-releasing hormone (GnRH) agonists used to reduce the production of sex hormones. They work by initially stimulating and then downregulating the pituitary gland’s secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased production of sex hormones such as testosterone and estrogen. This hormonal regulation leads to a significant reduction in the body’s natural production of sex hormones, making these drugs useful in various medical conditions. The main types of leuprorelin drugs include injections, tablets, and implants. Leuprorelin injections are pharmaceutical formulations of leuprorelin acetate given subcutaneously or intramuscularly to suppress sex hormones, used in treating prostate cancer, endometriosis, breast cancer, and early puberty. These are available in various dosage forms, such as depot injection and ready-to-use injections, and are administered either through intramuscular or subcutaneous routes. Leuprorelin drugs find applications in advanced prostate cancer, central precocious puberty, uterine fibroids, endometriosis, and others, serving a range of end users, including home care settings, hospitals, and specialty clinics.

What Is The Leuprorelin Drugs Market Growth Forecast?

The leuprorelin drugs market size is expected to see strong growth in the next few years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of extended-release implants and tablets, expansion of home care and specialty clinic administration, increasing pediatric hormonal therapy adoption, rising use of combination hormone therapy, integration of digital monitoring for treatment adherence. Major trends in the forecast period include rising adoption of depot injections and long-acting implants, growing awareness of hormonal therapies for prostate cancer and endometriosis, expansion of pediatric hormonal treatment programs, integration of subcutaneous and ready-to-use formulations, increased focus on home care and specialty clinic-based administration.

Global Leuprorelin Drugs Market Segmentation

1) By Type: Injections, Tablets, Implants 2) By Dosage Formulation: Depot Injection, Ready-To-Use Injections 3) By Route Of Administration: Intramuscular, Subcutaneous 4) By Application: Advanced Prostate Cancer, Central Precocious Puberty, Uterine Fibroids, Endometriosis, Other Applications 5) By End Users: Home Care Settings, Hospitals, Specialty Clinics Subsegments: 1) By Injections: Monthly Depot Injections, 3-Month Depot Injections, 6-Month Depot Injections, Pediatric Doses, Subcutaneous Injections, Intramuscular Injections, Pre-Filled Syringes, Multi-Dose Vials 2) By Tablets: Low-Dose Hormone Regulation Tablets, High-Dose Hormonal Suppression Tablets, Combination Hormone Therapy Tablets, Extended-Release Oral Tablets 3) By Implants: Biodegradable Polymer Implants, Non-Biodegradable Subdermal Implants, Short-Term Release Implants, Long-Term Release Implants, Implant Kits For Fertility Suppression, Pediatric Hormonal Implants

What Are The Drivers Of The Leuprorelin Drugs Market?

The increasing prevalence of prostate cancer is expected to propel the growth of the leuprorelin drugs market going forward. Prostate cancer refers to a type of cancer that develops in the prostate gland, a small gland in men located below the bladder and in front of the rectum. The rising prevalence of prostate cancer is due to the aging population, as the risk of developing prostate cancer increases significantly with age. Leuprorelin drugs support prostate cancer treatment by regulating hormone levels and slowing tumor growth. They improve patient outcomes through consistent dosing, reducing cancer progression, and enhancing quality of life. For instance, in January 2025, according to a report published by Prostate Cancer UK, a UK-based prostate cancer research, awareness, and support organization, in England, the number of prostate cancer diagnoses increased from 50,751 cases in 2022 to 55,033 cases in 2023, indicating a clear rise in annual incidence. Therefore, the increasing prevalence of prostate cancer is driving the growth of the leuprorelin drugs industry. The Increasing demand for in vitro fertilization (IVF) treatments is expected to propel the growth of the leuprorelin drugs market going forward. In vitro fertilization (IVF) treatments refer to assisted reproductive procedures in which an egg and sperm are combined outside the body in a laboratory to create an embryo, which is then transferred into the uterus to achieve pregnancy. Demand for in vitro fertilization (IVF) treatments is rising due to increasing delays in parenthood, which lead to higher age-related infertility and greater reliance on assisted reproductive methods. Increasing demand for in vitro fertilization (IVF) treatments supports leuprorelin drugs by significantly increasing the need for controlled ovarian stimulation and cycle-regulation protocols, in which leuprorelin is routinely used to suppress premature ovulation and optimize the timing and success of IVF procedures. For instance, in April 2025, according to the American Society for Reproductive Medicine, a US-based non-profit organization, in 2023, births resulting from IVF rose from 91,771 in 2022 to 95,860, making up 2.6% of all U.S. births. The number of IVF cycles performed at the 371 reporting SART clinics also grew, increasing from 389,993 in 2022 to 432,641 in 2023. Therefore, increasing demand for in vitro fertilization (IVF) treatments is driving the growth of the leuprorelin drugs industry.

Key Players In The Global Leuprorelin Drugs Market

Major companies operating in the leuprorelin drugs market are Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Limited, Lupin Limited, Livzon Pharmaceutical Group Inc., Alkem Laboratories Limited, Daewoong Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Gland Pharma Limited, Tolmar Pharmaceuticals Inc., Beijing Biote Pharmaceutical Co. Ltd., Accord Healthcare Limited, Intas Pharmaceuticals Limited, Foresee Pharmaceuticals Co Ltd., Samarth Life Sciences Private Limited

Global Leuprorelin Drugs Market Trends and Insights

Major companies operating in the leuprorelin drugs market are focusing on developing advanced formulations, such as ready-to-use injections, to improve patient convenience, enhance treatment adherence, and reduce preparation errors. Ready-to-use injections refer to pre-filled, sterile formulations of leuprolide acetate that eliminate the need for reconstitution, simplifying administration for healthcare providers and patients. For instance, in June 2025, Avenacy Inc., a US-based biopharmaceutical company, launched the leuprolide acetate injection, a synthetic hormone therapy used mainly for the palliative treatment of advanced prostate cancer. This ready-to-use formulation is designed to provide a convenient and reliable treatment option for patients and eliminates the need for manual mixing, reducing the risk of dosing errors and contamination while ensuring consistent therapeutic efficacy. It acts as a gonadotropin-releasing hormone (GnRH) agonist, initially increasing and then significantly reducing testosterone levels, which helps slow the growth of hormone-sensitive cancer cells.

Regional Insights

North America was the largest region in the leuprorelin drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Leuprorelin Drugs Market?

The leuprorelin drugs market consists of sales of products including depot formulations, microparticle suspension, prefilled syringes, and leuprolide acetate kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leuprorelin Drugs Market Report 2026?

The leuprorelin drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leuprorelin drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.